Purnama DI, Kusuma WLF, Purnama DK, Iswanto , Andrianto

Idioma: Inglés [English version]
Referencias bibliográficas: 41
Paginas: 149-156
Archivo PDF: 238.29 Kb.

RESUMEN

La deficiencia de vitamina D se ha asociado durante mucho tiempo con la incidencia de enfermedades cardiovasculares. También se cree que juega un papel en la gravedad de los pacientes con COVID-19. Se encuentra una concentración sérica de 25(OH)D < 50 nmol/L (deficiencia de vitamina D) en pacientes con manifestaciones graves de COVID-19 que requieren cuidados intensivos. Se cree que estos pacientes provienen de una respuesta inmune compleja no controlada. El papel de la vitamina D en la reacción de infección por COVID-19 es el apoyo a la respuesta de los péptidos antimicrobianos en el epitelio respiratorio y la reducción de las reacciones inflamatorias a la infección por SARS-CoV-2. Por lo tanto, puede reducir la gravedad de la infección por COVID-19. La vitamina D también se ha involucrado en varias enfermedades cardiovasculares que podrían aumentar la gravedad de la infección por COVID-19; es decir, hipertensión, metabolismo de lípidos, aterosclerosis e insuficiencia cardiaca. La vitamina D afecta la función de las células endoteliales, regulando así la vasodilatación de las células endoteliales dependientes. Puede prevenir la aterosclerosis y la calcificación vascular, a lo que los pacientes con COVID-19 tienen un mayor riesgo. También reduce las citocinas proinflamatorias, que tiene un efecto anti-remodelador para reducir el riesgo de muerte por obesidad e insuficiencia cardiaca entre los pacientes con COVID-19. Entendiendo la importancia de evitar la deficiencia de vitamina D, se debe tener en cuenta el cumplimiento de la ingesta diaria. La dosis diaria recomendada de vitamina D es de 200 UI al día para los menores de 50 años, 400 UI al día para los de 50 a 70 años y 600 UI para los mayores de 70 años. Se estima que por cada 100 UI de vitamina D, el nivel de 25(OH)D aumenta en 2.5 nmol/L

REFERENCIAS (EN ESTE ARTÍCULO)

1. Reddy Vanga S, Good M, Howard PA, Vacek JL. Role of vitamin D in cardiovascular health. Am J Cardiol. 2010; 106 (6): 798-805.

2. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, Almandoz JP et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96 (7): 1931-1942.

3. Al Mheid I, Patel R, Murrow J, Morris A, Rahman A, Fike L et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol. 2011; 58 (2): 186-192.

4. Anderson JL, Vanwoerkom RC, Horne BD, Bair TL, May HT, Lappé DL et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J. 2011; 162 (2): 331-339.e2.

5. Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol. 2011; 58 (14): 1433-1441.

6. Shafi AMA, Shaikh SA, Shirke MM, Iddawela S, Harky A. Cardiac manifestations in COVID-19 patients-a systematic review. J Card Surg. 2020; 35 (8): 1988-2008.

7. Jain A, Chaurasia R, Sengar NS, Singh M, Mahor S, Narain S. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep. 2020; 10 (1): 1-8.

8. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357 (3): 266-281.

9. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency. J Am Coll Cardiol. 2008; 52 (24): 1949-1956.

10. Lin L, Zhang L, Li C, Gai Z, Li Y. Vitamin D and vitamin D receptor: new insights in the treatment of hypertension. Curr Protein Pept Sci. 2019; 20 (10): 984-995.

11. Mozos I, Marginean O. Links between vitamin D deficiency and cardiovascular diseases. Biomed Res Int. 2015; 2015.

12. Chandran M, Chan Maung A, Mithal A, Parameswaran R. Vitamin D in COVID-19: dousing the fire or averting the storm? – A perspective from the Asia-Pacific. Osteoporos Sarcopenia. 2020; 6 (3): 97-105.

13. Sasikala T, Mukherjee B, Sahoo S, Sahoo AK. Vitamin-D deficiency as a predisposing cause for COVID-19. J Crit Rev. 2020; 7 (8): 2522-2526.

14. Biesalski HK. Vitamin D deficiency and co-morbidities in COVID-19 patients – A fatal relationship? NFS J. 2020; 20: 10-21.

15. Verdoia M, De Luca G. Potential role of hypovitaminosis D and vitamin D supplementation during COVID-19 pandemic. QJM. 2021; 114 (1): 3-10.

16. Stechschulte SA, Kirsner RS, Federman DG. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med. 2009; 122 (9): 793-802.

17. Lavie CJ, Lee JH, Milani R V. Vitamin D and cardiovascular disease. J Am Coll Cardiol. 2011; 58 (15): 1547-1556.

18. Lockhart SM, O'Rahilly S. When two pandemics meet: why is obesity associated with increased COVID-19 mortality? Med J. 2020; 1 (1): 33-42.

19. Abbas MA. Physiological functions of vitamin D in adipose tissue. J Steroid Biochem Mol Biol. 2017; 165: 369-381.

20. Pizzini A, Aichner M, Sahanic S, Bohm A, Egger A, Hoermann G et al. Impact of vitamin D deficiency on COVID-19-a prospective analysis from the CovILD registry. Nutrients. 2020; 12 (9): 2775.

21. Guessous I, Bochud M, Bonny O, Burnier M. Calcium, vitamin D and cardiovascular disease. Kidney Blood Press Res. 2011; 34 (6): 404-417.

22. Hernández JL, Nan D, Fernandez-Ayala M, García-Unzueta M, Hernández-Hernández MA, López-Hoyos M et al. Vitamin D status in hospitalized patients with SARS-CoV-2 infection. J Clin Endocrinol Metab. 2021; 106 (3): e1343-e1353.

23. Loffi M, Piccolo R, Regazzoni V, Di Tano G, Moschini L, Robba D et al. Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection. Open Heart. 2020; 7 (2): e001428.

24. De Smet D, De Smet K, Herroelen P, Gryspeerdt S, Martens GA. Serum 25(OH)D level on hospital admission associated with COVID-19 stage and mortality. Am J Clin Pathol. 2021; 155 (3): 381-388.

25. Zittermann A, Schleithoff SS, Gotting C, Dronow O, Fuchs U, Kuhn J et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail. 2008; 10 (3): 321-327.

26. Miller PD. Vitamin D, calcium, and cardiovascular mortality: a perspective from a plenary lecture given at the annual meeting of the American Association of Clinical Endocrinologists. Endocr Pract. 2011; 17 (5): 798-806.

27. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006; 83 (4): 754-759.

28. Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagn Microbiol Infect Dis. 2020; 98 (1): 115094.

29. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20 (6): 363-374.

30. Testa A, Mallamaci F, Benedetto FA, Pisano A, Tripepi G, Malatino L et al. Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. J Bone Miner Res. 2010; 25 (2): 313-319.

31. Weaver CM, Fleet JC. Vitamin D requirements: current and future. Am J Clin Nutr. 2004; 80 (6): 1735S-1739S.

32. Hall LM, Kimlin MG, Aronov PA, Hammock BD, Slusser JR, Woodhouse LR et al. Vitamin D intake needed to maintain target serum 25-hydroxyvitamin D concentrations in participants with low sun exposure and dark skin pigmentation is substantially higher than current recommendations. J Nutr. 2010; 140 (3): 542-550.

33. Ohaegbulam KC, Swalih M, Patel P, Smith MA, Perrin R. Vitamin D supplementation in COVID-19 patients: a clinical case series. Am J Ther. 2020; 27 (5): e485-e490.

34. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health. 2020; 13 (10): 1373-1380.

35. Ebadi M, Montano-Loza AJ. Perspective: improving vitamin D status in the management of COVID-19. Eur J Clin Nutr. 2020; 74 (6): 856-859.

36. Liu G, Hong T, Yang J. A single large dose of vitamin d could be used as a means of coronavirus disease 2019 prevention and treatment. Drug Des Devel Ther. 2020; 14: 3429-3434.

37. Annweiler C, Beaudenon M, Gautier J, Simon R, Dubée V, Gonsard J et al. Covid-19 and high-dose Vitamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial. Trials. 2020; 21 (1): 1031.

38. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007; 85 (1): 6-18.

39. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010; 303 (18): 1815-1822.

40. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007; 167 (16): 1730-1737.

41. Munshi R, Hussein MH, Toraih EA, Elshazli RM, Jardak C, Sultana N et al. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients. J Med Virol. 2021; 93 (2): 733-740.